RESET study showed the feasibility of sequential treatment in patients with EGFR-mutated advanced NSCLC, maximizing sustained clinical benefit and minimizing exposure to chemotherapy
Document ID: PC-VN-101786
13/10/2021
Author: Boehringer Ingelheim
123,000
Views
100k 340
NHỮNG NỘI DUNG LIÊN QUAN
PC-VN-101786
Production date: October 2021
Production date: October 2021